1-phenyl-benzimidazole compounds and their use as GABA-a receptor modulators
US6218547A · kind A · utility
Assignee
Inventors
Key dates
| Filing date | Mar 31, 1999 |
| Grant date | Apr 17, 2001 |
| Priority date | — |
| Expiry date | Mar 31, 2019 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D413/04
- WIPO fieldOrganic fine chemistry
- WIPO sectorChemistry
Abstract
The present invention relates to novel benzimidazole compounds, represented by general formula (I) in which o is 0, 1, 2 or 3; R.sup.1 represents an alkyl group, a phenyl group, or a monocyclic heterocyclic group, which groups may be substituted one or more times with substituents selected from alkyl, cycloalkyl, cycloalkyl-alkyl, alkoxy, halogen, trifluoromethyl, cyano, amino and nitro; or R.sup.1 represents a cyano group or a group of the formula -alkyl-CO.sub.2 R.sup.2, alkenyl-CO.sub.2 R.sup.2, --CO--R.sup.2, --CO.sub.2 (CH.sub.2).sub.m R.sup.2, or --C(R.sup.3).dbd.N--OR.sup.2, R.sup.11 represents a group of formula --CO.sub.2 --R.sup.9, or R.sup.11 represents a group of general formula (II) in which n is 0, 1, 2 or 3; or R.sup.11 may represent a group of general formula (III), in which n is 0, 1, 2 or 3; the novel compounds of the invention are useful in the treatment of central nervous system diseases and disorders, which are responsive to modulation of the GABA.sub.A receptor complex, such as for example anxiety, sleep disorders, anaestesia, memory disorders, and epilepsia or other convulsive disorders.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.